172 related articles for article (PubMed ID: 21398295)
21. Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection.
Collazos J; Mayo J; Ibarra S; Cazallas J
AIDS; 2003 Apr; 17(6):927-9. PubMed ID: 12660545
[No Abstract] [Full Text] [Related]
22. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection.
Martin-Carbonero L; de Ledinghen V; Moreno A; Maida I; Foucher J; Barreiro P; Romero M; Satta G; Garcia-Samaniego J; Gonzalez-Lahoz J; Soriano V
J Viral Hepat; 2009 Nov; 16(11):790-5. PubMed ID: 19413693
[TBL] [Abstract][Full Text] [Related]
23. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.
Stone SF; Lee S; Keane NM; Price P; French MA
J Infect Dis; 2002 Nov; 186(10):1498-502. PubMed ID: 12404169
[TBL] [Abstract][Full Text] [Related]
24. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
25. High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
Bani-Sadr F; Goderel I; Morand P; Payan C; Lunel F; Pol S; Perronne C; Carrat F; Cacoub P
AIDS; 2007 Jul; 21(12):1645-8. PubMed ID: 17630563
[TBL] [Abstract][Full Text] [Related]
26. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome.
Castellares C; Barreiro P; Martín-Carbonero L; Labarga P; Vispo ME; Casado R; Galindo L; García-Gascó P; García-Samaniego J; Soriano V
J Viral Hepat; 2008 Mar; 15(3):165-72. PubMed ID: 18233989
[TBL] [Abstract][Full Text] [Related]
27. [CROI 2012: updates on raltegravir].
MMW Fortschr Med; 2012 May; 154 Suppl 1():41. PubMed ID: 22916600
[No Abstract] [Full Text] [Related]
28. Survival of HIV-infected patients with compensated liver cirrhosis.
Tuma P; Jarrin I; Del Amo J; Vispo E; Medrano J; Martin-Carbonero L; Labarga P; Barreiro P; Soriano V
AIDS; 2010 Mar; 24(5):745-53. PubMed ID: 20154579
[TBL] [Abstract][Full Text] [Related]
29. Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C.
Macías J; Mira JA; Vergara S; Pineda JA
Hepatology; 2005 Aug; 42(2):498; author reply 498-9. PubMed ID: 15880585
[No Abstract] [Full Text] [Related]
30. Raltegravir: is a 400 mg once-daily dose enough?
Lanzafame M; Hill A; Lattuada E; Calcagno A; Bonora S
J Antimicrob Chemother; 2010 Mar; 65(3):595-7. PubMed ID: 20071368
[No Abstract] [Full Text] [Related]
31. Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients.
Perrella A; Sbreglia C; D'Antonio A; Atripaldi L; Perrella O
Clin Microbiol Infect; 2010 Jun; 16(6):676-8. PubMed ID: 19681945
[TBL] [Abstract][Full Text] [Related]
32. [Morphological liver changes of chronic hepatitis C in antiretroviral-naive HIV-infected patients].
Grabczewska E; Pawłowska M
Przegl Epidemiol; 2005; 59(2):423-30. PubMed ID: 16190550
[TBL] [Abstract][Full Text] [Related]
33. Low frequency of skin reactions in a cohort of patients on raltegravir.
Bonfanti P; Ricci E; Molteni C; De Socio GV; Rusconi S; Vichi F; Penco G; Antinori A; Cordier L; Maggi P; Celesia BM; Grosso C; Quirino T
J Antimicrob Chemother; 2012 Jul; 67(7):1800-2. PubMed ID: 22441576
[No Abstract] [Full Text] [Related]
34. [Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance].
Pol S
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B264-73. PubMed ID: 12180300
[No Abstract] [Full Text] [Related]
35. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
[TBL] [Abstract][Full Text] [Related]
36. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection.
Vallet-Pichard A; Pol S
J Hepatol; 2006; 44(1 Suppl):S28-34. PubMed ID: 16343684
[TBL] [Abstract][Full Text] [Related]
37. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
38. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
Manosuthi W; Chumpathat N; Chaovavanich A; Sungkanuparph S
BMC Infect Dis; 2005 Aug; 5():67. PubMed ID: 16120209
[TBL] [Abstract][Full Text] [Related]
39. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
[TBL] [Abstract][Full Text] [Related]
40. HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article.
Petrovic LM
Liver Int; 2007 Jun; 27(5):598-606. PubMed ID: 17498243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
